STOCKWATCH: Roche's old school scheme traps investors in young Puma
This article was originally published in Scrip
There are some good old school tricks in pharmaceutical development, like publishing patents for sub-optimal compounds to send your competitors off into unproductive areas of chemical space. These tricks aren't written down anywhere (apart from that one) but are stored in the collective experience of old heads in the pharma jungle. Sometimes young cubs in biotechnology who don't know the old ways tricks fall straight into the traps that they could have avoided. This is what seems to have to Puma Biotechnology, the 'trendingest' entity in biotech last week.